AYTU BIOPHARMA, INC Income (Loss) from Continuing Operations, Per Diluted Share
AYTU BIOPHARMA, INC (AYTU) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.53 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-05-13
- AYTU BIOPHARMA, INC income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$0.53, a 365.00% decline year-over-year.
- AYTU BIOPHARMA, INC income (loss) from continuing operations, per diluted share for the quarter ending 2025-12-31 was -$1.05.
- AYTU BIOPHARMA, INC income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was -$0.08.
- AYTU BIOPHARMA, INC income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was $0.20.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month |
|---|---|---|---|
| 2026-03-31 | -$0.53 10-Q · filed 2026-05-13 | -$1.42 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$1.05 10-Q · filed 2026-02-03 | -$0.89 10-Q · filed 2026-02-03 | |
| 2025-09-30 | -$0.08 10-Q · filed 2025-11-13 | ||
| 2025-03-31 | $0.20 10-Q · filed 2026-05-13 | -$0.29 10-Q · filed 2026-05-13 | |
| 2024-12-31 | -$0.28 10-Q · filed 2026-02-03 | -$0.47 10-Q · filed 2026-02-03 | |
| 2024-09-30 | -$0.20 10-Q · filed 2025-11-13 | ||
| 2024-03-31 | -$0.41 10-Q · filed 2025-05-14 | -$1.66 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $0.11 10-Q · filed 2025-02-12 | -$1.25 10-Q · filed 2025-02-12 | |
| 2023-09-30 | -$1.36 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |